Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2013

01.03.2013 | Pancreatic Tumors

Re-resection for Isolated Local Recurrence of Pancreatic Cancer is Feasible, Safe, and Associated with Encouraging Survival

verfasst von: Oliver Strobel, MD, Werner Hartwig, MD, Thilo Hackert, MD, Ulf Hinz, MSc, Viktoria Berens, Lars Grenacher, MD, Frank Bergmann, MD, Jürgen Debus, MD, Dirk Jäger, MD, Markus Büchler, MD, Jens Werner, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Local recurrence of pancreatic cancer occurs in 80 % of patients within 2 years after potentially curative resections. Around 30 % of patients have isolated local recurrence (ILR) without evidence of metastases. In spite of localized disease these patients usually only receive palliative chemotherapy and have a short survival.

Purpose

To evaluate the outcome of surgery as part of a multimodal treatment for ILR of pancreatic cancer.

Methods

All consecutive operations performed for suspected ILR in our institution between October 2001 and October 2009 were identified from a prospective database. Perioperative outcome, survival, and prognostic parameters were assessed.

Results

Of 97 patients with histologically proven recurrence, 57 (59 %) had ILR. In 40 (41 %) patients surgical exploration revealed metastases distant to the local recurrence. Resection was performed in 41 (72 %) patients with ILR, while 16 (28 %) ILR were locally unresectable. Morbidity and mortality were 25 and 1.8 % after resections and 10 and 0 % after explorations, respectively. Median postoperative survival was 16.4 months in ILR versus 9.4 months in metastatic disease (p < 0.0001). In ILR median survival was significantly longer after resection (26.0 months) compared with exploration without resection (10.8 months, p = 0.0104). R0 resection was achieved in 18 patients and resulted in 30.5 months median survival. Presence of metastases, incomplete resection, and high preoperative CA 19-9 serum values were associated with lesser survival.

Conclusions

Resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with favorable survival outcome. This concept warrants further evaluation in other institutions and in randomized controlled trials.
Literatur
1.
Zurück zum Zitat American Cancer Society. Cancer Facts & Figures. Atlanta: American Cancer Society; 2010. American Cancer Society. Cancer Facts & Figures. Atlanta: American Cancer Society; 2010.
2.
Zurück zum Zitat Krebs in Deutschland 2005/2006. Haufigkeiten und Trends. 7. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg). Berlin; 2010. Krebs in Deutschland 2005/2006. Haufigkeiten und Trends. 7. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg). Berlin; 2010.
3.
Zurück zum Zitat Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012;99:1036–49.PubMedCrossRef Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012;99:1036–49.PubMedCrossRef
4.
Zurück zum Zitat Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–8.PubMedCrossRef Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–8.PubMedCrossRef
5.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.PubMedCrossRef Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.PubMedCrossRef
6.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.PubMedCrossRef Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.PubMedCrossRef
7.
Zurück zum Zitat Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450–6.PubMedCrossRef Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450–6.PubMedCrossRef
8.
Zurück zum Zitat Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.PubMedCrossRef Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.PubMedCrossRef
9.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.PubMedCrossRef Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.PubMedCrossRef
11.
Zurück zum Zitat Hashimoto K, Ueno H, Ikeda M, et al. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology. 2009;77:217–23.PubMedCrossRef Hashimoto K, Ueno H, Ikeda M, et al. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology. 2009;77:217–23.PubMedCrossRef
12.
Zurück zum Zitat Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72:2118–23.PubMedCrossRef Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72:2118–23.PubMedCrossRef
13.
Zurück zum Zitat Maemura K, Shinchi H, Noma H, et al. Chemoradiotherapy for locally recurrence after primary resection of biliary-pancreatic cancer. Gan To Kagaku Ryoho. 2009;36:265–8.PubMed Maemura K, Shinchi H, Noma H, et al. Chemoradiotherapy for locally recurrence after primary resection of biliary-pancreatic cancer. Gan To Kagaku Ryoho. 2009;36:265–8.PubMed
14.
Zurück zum Zitat Obuchi T, Sasaki A, Shimooki O, et al. Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy. Gan To Kagaku Ryoho. 2009;36:991–4.PubMed Obuchi T, Sasaki A, Shimooki O, et al. Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy. Gan To Kagaku Ryoho. 2009;36:991–4.PubMed
15.
Zurück zum Zitat Wilkowski R, Thoma M, Bruns C, Duhmke E, Heinemann V. Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP. 2006;7:34–40.PubMed Wilkowski R, Thoma M, Bruns C, Duhmke E, Heinemann V. Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP. 2006;7:34–40.PubMed
16.
Zurück zum Zitat Minari Y, Nio Y, Endo S, Yano S, Itakura M, Yamasawa K, Tamura K. A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy. Gan To Kagaku Ryoho. 2000;27:121–5.PubMed Minari Y, Nio Y, Endo S, Yano S, Itakura M, Yamasawa K, Tamura K. A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy. Gan To Kagaku Ryoho. 2000;27:121–5.PubMed
17.
Zurück zum Zitat Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z’graggen K. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg. 2003;138:1310–4.PubMedCrossRef Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z’graggen K. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg. 2003;138:1310–4.PubMedCrossRef
18.
Zurück zum Zitat Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10–5.PubMedCrossRef Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10–5.PubMedCrossRef
19.
Zurück zum Zitat Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg. 1995;130:295–9.PubMedCrossRef Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg. 1995;130:295–9.PubMedCrossRef
20.
Zurück zum Zitat Hartwig W, Hackert T, Hinz U, Hassenpflug M, Strobel O, Buchler MW, et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg. 2009;250:81–7.PubMedCrossRef Hartwig W, Hackert T, Hinz U, Hassenpflug M, Strobel O, Buchler MW, et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg. 2009;250:81–7.PubMedCrossRef
21.
Zurück zum Zitat Tseng JF, Tamm EP, Lee JE, Pisters PW, Evans DB. Venous resection in pancreatic cancer surgery. Best Pract Res Clin Gastroenterol. 2006;20:349–64.PubMedCrossRef Tseng JF, Tamm EP, Lee JE, Pisters PW, Evans DB. Venous resection in pancreatic cancer surgery. Best Pract Res Clin Gastroenterol. 2006;20:349–64.PubMedCrossRef
22.
Zurück zum Zitat Ibusuki M, Hiraoka T, Kanemitsu K, Takamori H, Tsuji T. Complete remission of pancreatic cancer after multiple resections of locally pancreatic recurrent sites and liver metastasis: report of a case. Surg Today. 2008;38:563–6.PubMedCrossRef Ibusuki M, Hiraoka T, Kanemitsu K, Takamori H, Tsuji T. Complete remission of pancreatic cancer after multiple resections of locally pancreatic recurrent sites and liver metastasis: report of a case. Surg Today. 2008;38:563–6.PubMedCrossRef
23.
Zurück zum Zitat Inoue K, Kosuge T, Shimada K, Yamamoto J, Takayama T, Ozaki H, et al. Repeated radical resection and intraoperative irradiation for recurrent pancreatic ductal adenocarcinoma after pancreatoduodenectomy. Surgery. 1995;118:909–11.PubMedCrossRef Inoue K, Kosuge T, Shimada K, Yamamoto J, Takayama T, Ozaki H, et al. Repeated radical resection and intraoperative irradiation for recurrent pancreatic ductal adenocarcinoma after pancreatoduodenectomy. Surgery. 1995;118:909–11.PubMedCrossRef
24.
Zurück zum Zitat Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007;245:566–72.PubMedCrossRef Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007;245:566–72.PubMedCrossRef
25.
Zurück zum Zitat Seelig MH, Janot M, Chromik AM, et al. Redo-surgery following curative resection of pancreatic carcinoma: the difference between true and suspected recurrence. Dig Surg. 2009;26:222–8.PubMedCrossRef Seelig MH, Janot M, Chromik AM, et al. Redo-surgery following curative resection of pancreatic carcinoma: the difference between true and suspected recurrence. Dig Surg. 2009;26:222–8.PubMedCrossRef
26.
Zurück zum Zitat Heye T, Zausig N, Klauss M, et al. CT diagnosis of recurrence after pancreatic cancer: Is there a pattern? World J Gastroenterol. 2011;17:1126–34.PubMedCrossRef Heye T, Zausig N, Klauss M, et al. CT diagnosis of recurrence after pancreatic cancer: Is there a pattern? World J Gastroenterol. 2011;17:1126–34.PubMedCrossRef
27.
Zurück zum Zitat Hartwig W, Schneider L, Diener MK, Bergmann F, Buchler MW, Werner J. Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg. 2009;96:5–20.PubMedCrossRef Hartwig W, Schneider L, Diener MK, Bergmann F, Buchler MW, Werner J. Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg. 2009;96:5–20.PubMedCrossRef
28.
Zurück zum Zitat Strobel O, Berens V, Hinz U, et al. Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 2012;152:S33–42.PubMedCrossRef Strobel O, Berens V, Hinz U, et al. Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 2012;152:S33–42.PubMedCrossRef
29.
Zurück zum Zitat Fernandez-Cruz L, Johnson C, Dervenis C. Locoregional dissemination and extended lymphadenectomy in pancreatic cancer. Dig Surg. 1999;16:313–9.PubMedCrossRef Fernandez-Cruz L, Johnson C, Dervenis C. Locoregional dissemination and extended lymphadenectomy in pancreatic cancer. Dig Surg. 1999;16:313–9.PubMedCrossRef
30.
Zurück zum Zitat Tempero MA, Arnoletti JP, Behrman S, et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010;8:972–1017.PubMed Tempero MA, Arnoletti JP, Behrman S, et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010;8:972–1017.PubMed
Metadaten
Titel
Re-resection for Isolated Local Recurrence of Pancreatic Cancer is Feasible, Safe, and Associated with Encouraging Survival
verfasst von
Oliver Strobel, MD
Werner Hartwig, MD
Thilo Hackert, MD
Ulf Hinz, MSc
Viktoria Berens
Lars Grenacher, MD
Frank Bergmann, MD
Jürgen Debus, MD
Dirk Jäger, MD
Markus Büchler, MD
Jens Werner, MD
Publikationsdatum
01.03.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2762-z

Weitere Artikel der Ausgabe 3/2013

Annals of Surgical Oncology 3/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.